AH-1058 free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 591441

CAS#: 300347-11-9

Description: AH-1058 free base is a biochemical.


Chemical Structure

img
AH-1058 free base
CAS# 300347-11-9

Theoretical Analysis

MedKoo Cat#: 591441
Name: AH-1058 free base
CAS#: 300347-11-9
Chemical Formula: C30H28N2O3
Exact Mass: 464.21
Molecular Weight: 464.570
Elemental Analysis: C, 77.56; H, 6.08; N, 6.03; O, 10.33

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: AH-1058 free base; AH 1058 free base; AH1058 free base

IUPAC/Chemical Name: Piperidine, 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-((2E)-3-(3-methoxy-2-nitrophenyl)-2-propen-1-yl)-

InChi Key: HLPYTHVNPSSCNQ-YRNVUSSQSA-N

InChi Code: InChI=1S/C30H28N2O3/c1-35-28-14-6-10-25(30(28)32(33)34)11-7-19-31-20-17-24(18-21-31)29-26-12-4-2-8-22(26)15-16-23-9-3-5-13-27(23)29/h2-16H,17-21H2,1H3/b11-7+

SMILES Code: O=[N+](C1=C(OC)C=CC=C1/C=C/CN2CC/C(CC2)=C3C4=CC=CC=C4C=CC5=CC=CC=C/35)[O-]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 464.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Dohmoto H, Takahara A, Uneyama H, Yoshimoto R. Cardiac Ca(2+) channel-blocking effects of the cyproheptadine derivative AH-1058 in isolated guinea pig cardiomyocytes. J Pharmacol Sci. 2003 Feb;91(2):163-6. PubMed PMID: 12686762.

2: Takahara A, Sugiyama A, Yoshimoto R, Hashimoto K. AH-1058: a novel cardioselective Ca2+ channel blocker. Cardiovasc Drug Rev. 2001 Winter;19(4):279-96. Review. PubMed PMID: 11830748.

3: Takahara A, Hirasawa A, Dohmoto H, Shoji M, Yoshimoto R, Sugiyama A, Hashimoto K. In vivo antiarrhythmic profile of AP-792 assessed in different canine arrhythmia models. Jpn J Pharmacol. 2001 Sep;87(1):21-6. PubMed PMID: 11676194.

4: Takahara A, Dohmoto H, Yoshimoto R, Sugiyama A, Hashimoto K. Utilization of telemetry system to assess the cardiovascular profile of AH-1058, a new cardioselective Ca2+ channel blocker, in conscious dogs. Jpn J Pharmacol. 2001 Mar;85(3):331-4. PubMed PMID: 11325028.

5: Takahara A, Dohmoto H, Yoshimoto R, Sugiyama A, Hashimoto K. Cardiovascular action of a cardioselective Ca(2+)channel blocker AH-1058 in conscious dogs assessed by telemetry. Eur J Pharmacol. 2001 Feb 9;413(1):101-8. PubMed PMID: 11173068.

6: Takahara A, Sugiyama A, Dohmoto H, Yoshimoto R, Hashimoto K. Electrophysiological and cardiohemodynamic effects of AH-1058, a new type calcium channel blocker, assessed by the in vivo canine model. Jpn J Pharmacol. 2000 Jun;83(2):107-12. PubMed PMID: 10928322.

7: Takahara A, Sugiyama A, Dohmoto H, Yoshimoto R, Hashimoto K. Antiarrhythmic and cardiohemodynamic effects of a novel Ca(2+) channel blocker, AH-1058, assessed in canine arrhythmia models. Eur J Pharmacol. 2000 Jun 9;398(1):107-12. PubMed PMID: 10856454.

8: Takahara A, Sugiyama A, Dohmoto H, Yoshimoto R, Hashimoto K. Comparison of cardiovascular effects of a new calcium channel blocker AH-1058 with those of verapamil assessed in blood-perfused canine heart preparations. J Cardiovasc Pharmacol. 2000 May;35(5):741-8. PubMed PMID: 10813376.

9: Tanaka H, Ichikawa T, Matsui S, Okazaki K, Masumiya H, Kawanishi T, Shigenobu K. Calcium channel antagonistic effects of AH-1058, a novel antiarrhythmic drug, on guinea-pig myocardium. Res Commun Mol Pathol Pharmacol. 1999;104(1):13-21. PubMed PMID: 10604274.

10: Takahara A, Uneyama H, Sasaki N, Ueda H, Dohmoto H, Shoji M, Hara Y, Nakaya H, Yoshimoto R. Effects of AH-1058, a new antiarrhythmic drug, on experimental arrhythmias and cardiac membrane currents. J Cardiovasc Pharmacol. 1999 Apr;33(4):625-32. PubMed PMID: 10218734.